Draft Genetic Testing Policies - Blue Advantage®
Blue Cross and Blue Shield of Alabama partners with Carelon Medical Benefits Management, an independent company, to administer genetic testing solutions for our customers.
Carelon is our business associate and has agreed to follow our privacy and security policies regarding the confidentiality and protection of your personal health information.
Draft Genetic Testing Policies
Effective for dates of service on or after July 25, 2025, the changes listed in the document below will apply to Carelon Genetic Testing Clinical Appropriateness Guidelines. As part of the Carelon guidelines semi-annual review process, these updates are focused on advancing efforts to drive clinically appropriate, safe and affordable healthcare services.
Clicking "Accept" will take you to a website operated by Carelon Medical Benefits Management.
Comment on Draft Policies
To ensure that the development of medical policies occurs through an open, collaborative process, we welcome comments about medical policies that are in the draft stage.
Participating providers are invited to submit scientific, evidence-based information, professional consensus opinions and other information supported by medical literature relevant to these draft policies for consideration.
Comments are accepted for 45 days from the posting date listed on the draft policy.
Make sure your voice is heard by providing feedback directly to us:
- Complete our online medical policy feedback form, or
- Send comments by mail or fax to:
Blue Cross and Blue Shield of Alabama
Attn: Health Management - Medical Policy
P.O. Box 995
Birmingham, AL 35298-0001
Fax: 205-220-0878